10.61
-0.22 (-2.03%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Sagimet Biosciences Inc. - Seri | 混合的 | 看跌 |
AIStockmoo 评分
| 价值 35% | 0.0 |
| AI Insight 参考 | NA |
| 相对估值 参考 | NA |
| 财务健康 参考 | 0.0 |
| 时机 35% | 3.4 |
| AI Technical 参考 | NA |
| 技术振荡指标 参考 | 4.0 |
| 技术平均移动指标 参考 | 2.5 |
| 聪明钱 30% | 0.0 |
| 分析师共识 参考 | 0.0 |
| 内部交易活动 参考 | NA |
| 市场环境 | ×0.79 |
| 宏观环境 参考 | -3.3 |
| 行业对比大市 (6个月) | -17.9% |
| 支柱一致性 | ×1.00 |
| 不计入评分 | |
| 价格波动 参考 | -5.0 |
| 最终评分 | 0.94 |
|
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 13.03% |
| 机构持股比例 | 44.74% |
该时间范围内无数据。
该时间范围内无数据。
投资组合